Purpose of review Anti-nerve growth factor (NGF) antibodies hold tremendous potential for the management of osteoarthritis pain, but clinical trials have revealed serious adverse effects that are incompletely understood. This review discusses clinical trial results along with preclinical studies that have assessed NGF blockade in experimental osteoarthritis, in order to provide insight for future studies.
INTRODUCTION
Nerve growth factor (NGF) was discovered by Rita Levi-Montalcini in 1952, and her subsequent work with Stanley Cohen in the 1950s demonstrated that this soluble factor controlled the growth and development of the nervous system [1] . In the 1990s, it was recognized that in adults, NGF plays a role in tissue injury and pain [2, 3] . As a member of the neurotrophin family, NGF can bind the general neurotrophin receptor p75, as well as its highaffinity cognate receptor, tropomyosin-related kinase (Trk)A [4] . The NGF-TrkA pathway in particular appears to be critical in driving acute and chronic pain [4] . In addition to the nervous system, NGF can be expressed by and act on a variety of nonneuronal cells, including inflammatory cells, keratinocytes, endothelial cells [4] , and cells within the joint such as chondrocytes [5] . This narrative review will briefly discuss results from anti-NGF clinical trials for osteoarthritis pain. In addition, we will review the emerging literature on the effects of NGF blockade in experimental models of osteoarthritis, in order to examine whether preclinical observations can provide insight into the clinical findings, in particular the reported adverse effects. We searched PubMed for the following keywords: 'Nerve growth factor', 'TrkA', 'osteoarthritis', 'pain', 'clinical trials', 'animal models'. The basic mechanisms of action of NGF, the effects of NGF blockade in preclinical models of other types of pain, and details on expression of NGF and TrkA in the joint are beyond the scope of this review, but other recent reviews covering these topics are available [3] [4] [5] [6] .
NERVE GROWTH FACTOR TARGETED THERAPY: CLINICAL IMPLICATIONS
Inadequate pain relief is the most troubling aspect of osteoarthritis to patients and is responsible for the majority of osteoarthritis-related physician visits. Concerns about potential risks with prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) and opiates have left the therapeutic armamentarium for osteoarthritis grossly depleted. As such, pain control remains the most significant unmet need in osteoarthritis management.
NGF has long been an attractive therapeutic target for osteoarthritis pain, and expectations increased following publication of the first well-powered controlled trial of anti-NGF therapy in osteoarthritis in 2010 [7] . Shortly afterwards, however, the US Food and Drug Administration (FDA) imposed a hold on all clinical trials of NGF antagonists because of reports of rapidly progressive osteoarthritis and of osteonecrosis among patients receiving these agents; subsequently, this hold was extended as a result of observations of autonomic nervous damage in preclinical models [8] . The hold was ultimately lifted in 2015, and development targeted at refractory knee or hip osteoarthritis pain is again proceeding rapidly.
There are at least four monoclonal antibody (mAb)-based NGF antagonists in various stages of development; tanezumab is the most advanced and is in Phase III clinical trials, whereas fulranumab, fasinumab, and ABT-110 (or PG110) are in earlier stages [9] . Nonetheless, a search of clinicaltrials.gov suggested that only tanezumab was in active trials for osteoarthritis as of August 2016. Each of these agents likely has substantial efficacy in palliating osteoarthritis pain. Although they have been tested in a variety of other painful conditions, including chronic lower back pain and neuropathic pain [10] , it appears that they have their greatest effect in osteoarthritis pain.
Efficacy
Two recent systematic reviews have each confirmed that inhibition of NGF through targeted mAb therapy effectively relieves pain and improves function in osteoarthritis. Schnitzer and Marks [11 & ] reviewed the efficacy of all three anti-NGF agents in clinical development whereas Kan et al. [12 & ] restricted their analysis to the use of tanezumab in osteoarthritis of the knee. The former identified 13 multicenter placebo-controlled trials of osteoarthritis of the hip or knee that met their inclusion criteria, including an unpublished study that had been presented in abstract form (since published [13] ), whereas the latter identified only four studies of tanezumab in knee osteoarthritis that met their inclusion criteria. All studies in both reviews were funded by the pharmaceutical industry. The conclusions of each review, however, were similar: compared to placebo, NGF inhibition yielded substantial pain improvement, with standardized mean differences in the 0.35-0.5 range. Moreover, function, as assessed by the Western Ontario and McMaster Universities Arthritis Index function subscale, was also improved. In studies of tanezumab monotherapy compared with either NSAIDs or with opiates, tanezumab in doses of 5 and 10 mg were statistically significantly superior to the active comparators, with standardized effect sizes of 0.22-0.24 [11 & ,14] .
Risks
Although anti-NGF therapy has been shown to be efficacious in osteoarthritis, safety concerns led to the US FDA hold on all clinical testing in 2010. These were based on reports of rapidly progressive osteoarthritis and of osteonecrosis among patients who had received anti-NGF therapy, including involvement of joints without known osteoarthritis. Detailed reviews of the adverse events reported during clinical trials with tanezumab and fulranumab were performed by an expert adjudication committee funded by Pfizer. A dose-response relationship was noted between the serious events (progressive osteoarthritis and reported osteonecrosis) and doses of tanezumab between 2.5 and 10 mg
KEY POINTS
Anti-NGF therapy has been shown to improve pain and function in osteoarthritis patients.
High doses of anti-NGF, and combination of anti-NGF with NSAIDs have been reported to increase the risk of rapidly progressive osteoarthritis.
Preclinical studies testing NGF blockade have supported the clinical trial findings of improved pain.
Some preclinical studies report increased joint damage with NGF blockade.
Mechanisms of adverse effects are not understood, and detailed preclinical studies will be needed to elucidate them. [15] , and this has resulted in dose reductions in subsequent trials; the current maximum dose is 5 mg. Interestingly, the incidence of osteonecrosis may be lower than previously thought. Of the 86 reported cases of osteonecrosis, the Pfizer-funded adjudication committee could demonstrate unambiguous osteonecrosis in only two (though eight had insufficient information to distinguish primary osteonecrosis and the committee failed to reach consensus on another five) [16 && ]. Importantly, the risk of developing rapidly progressive osteoarthritis appeared to be significantly greater when tanezumab was used in conjunction with NSAIDs, compared with tanezumab monotherapy [15, 16 && ]. This observation has resulted in strict limits on the duration of NSAID use during exposure to anti-NGF therapy in subsequent trials.
Notwithstanding the risks, cost-effectiveness analyses suggest that the pain palliation provided by anti-NGF therapy is sufficiently significant that even a rate of rapidly progressive osteoarthritis occurring in up to 10% of patients would not nullify the overall improvement in quality-adjusted life years (QALY) achieved [17] , and that anti-NGF therapy could be cost effective at up to $400 per dose [17] .
PRECLINICAL TESTING OF NERVE GROWTH FACTOR BLOCKADE IN ANIMAL MODELS OF OSTEOARTHRITIS
In an attempt to gain a deeper understanding of the observed efficacy and adverse effects in clinical trials, we reviewed the literature on NGF blockade in preclinical osteoarthritis models. Although clinical trials for osteoarthritis pain have been ongoing since 2008, the preclinical literature testing the effects of NGF blockade (either through neutralizing antibodies or through blockade of TrkA) in animal models of osteoarthritis has lagged behind, with the majority of reports published in the past year. We identified eight published reports in experimental models of osteoarthritis: the earlier studies solely assessed the effect of NGF blockade on pain behaviors, while more recent studies measured both pain behaviors and effects on the affected joint (summarized in Table 1 ). For details on the osteoarthritis models and pain behavior assays utilized in these studies, please see a recent review [18] . In addition, two recent veterinary trials are discussed.
Preclinical studies analyzing effects on pain behaviors
Our search identified four studies that assessed the effect of NGF blockade in experimental models of osteoarthritis. In each case only a single pain-related behavior was analyzed in the animals ( Table 1 ). The first report of NGF blockade in an animal model of osteoarthritis examined the effect of a single systemic injection of a soluble NGF receptor fragment containing the NGF binding domain, TrkAd5, on weight-bearing deficit in the chronic phase (week 16) of the mouse destabilization of the medial meniscus (DMM) model, and reported a reversal of weight-bearing deficits that lasted for 3 days [19] . In the rat mono-iodoacetate (MIA) model, a single intra-articular injection of a small molecule TrkA inhibitor (GZ389988) 7 days after induction of the model resulted in long-term reduction of weight-bearing deficits [20] . Interestingly, intra-articular injection into the contralateral joint had no effect on weight-bearing in the ipsilateral limb, suggesting that intra-articular injection does not result in substantial systemic exposure, which may limit the risk of adverse effects. A first-in-human study with ascending single intra-articular doses of GZ389988 in patients with painful osteoarthritis of the knee has recently commenced (https://clinical trials.gov/ct2/show/NCT02424942?term=trka+and+ osteoarthritis&rank=1).
Only two preclinical studies report the use of neutralizing antibodies against NGF. In the rat MIA model, a single systemic injection of an anti-NGF mAb shortly after model induction (day 2) was able to reverse deficits in burrowing 1 day later compared to isotonic saline [21] ; the effect of isotype control antibody was not assessed. Finally, one study [22] reported the effect of repeated intra-articular administration of an anti-NGF antibody into the knee of PKCd null mice that underwent DMM surgery (injections started 2 weeks after surgery, twice a week, for 6 weeks). The effects of anti-NGF antibody in wild-type mice were not reported in this study. PKCd null showed more severe mechanical allodynia after DMM than wild-type mice, despite less pronounced cartilage damage, and repeated intraarticular administration of anti-NGF decreased established mechanical allodynia of the hind paw compared to PKCd null mice injected with isotonic saline; the effect of isotype control antibody was not assessed. It should be considered that inclusion of isotype control antibodies may be important when assessing pain-related outcomes, since immunoglobulins have well documented anti-inflammatory and potentially analgesic effects [29, 30] .
Preclinical studies analyzing effects on pain behaviors and joint structure
In light of the reported adverse events in clinical trials, it is clearly warranted that preclinical studies Treatment on day 3 decreases gait imbalances on day 35 after MIA induction (doses 0.3 and 1 mg/kg) compared with saline; treatment on day 3 or day 14 decreased gait changes on day 21; treatment 1 h or 24 h before gait testing on day 21 had no effect; treatment on day 3 caused increase in knee diameter on day 35; no effect on macroscopic scoring of tibial surface on day 35 Ishikawa et al. [23] Nerve growth factor blockade for osteoarthritis pain Miller et al. not only assess the effects on pain-related outcomes but also include assessment of the joint. In the past year, four publications evaluated effects of anti-NGF antibodies or TrkA inhibition on both pain behavior and some aspect of joint structural integrity (Table 1) . A single systemic injection of an anti-NGF antibody (AS2886401-00) on day 3 after MIA induction in rats decreased gait changes by day 35, compared to vehicle; an isotype control antibody was not tested [23] . Treatment caused an increase in knee diameter (day 35), but there was no effect on macroscopic tibial cartilage damage; joint histology was not performed. Two recent papers evaluated the effect of longterm NGF blockade in rat meniscal surgery models.
Nwosu et al. [24] studied the effect of an oral TrkA inhibitor, AR786. Prophylactic treatment [1 day prior to transection of the medial meniscus (MNX) surgery until day 28 postsurgery] prevented development of weight-bearing asymmetry and mechanical allodynia of the hind paw, and showed a trend toward an increase in macroscopic chondropathy and microscopic synovitis by day 28, but statistics comparing the inhibitor-treated rats to vehicle-treated rats were not presented [24] . Therapeutic treatment (days 14-21) successfully reversed weight-bearing asymmetry and mechanical allodynia of the hind paw, while no short-term effect on macroscopic chondropathy or histologic cartilage degeneration was observed [24] . There was Improved activity levels in cats for 6 weeks; overall, there was a strong placebo effect, but owner assessments of the treatment group improved at week 3 compared with placebo (saline); no adverse events over 6-week period
Gruen et al. [28] hNGF, human nerve growth factor; IgG, immunoglobulin; MIA, mono-iodoacetate; NGF, nerve growth factor; TRAP, tartrate resistant acid phosphatase; TrkA, tropomyosin-related kinase A.
a trend toward decreased knee swelling and an increased histological calcified cartilage and subchondral bone damage score (includes subchondral bone sclerosis as well as fragmentation of calcified cartilage [24, 31] ), although statistics were not presented [24] . Similar findings were recently reported using tanezumab in a 28-day rat medial meniscal tear (MMT) model [25 && ]. LaBranche et al. [25 && ] tested the effect of prophylactic administration of tanezumab and found a positive effect on gait deficiency 3-8 days after surgery, but this was accompanied by a significant increase in tibial cartilage degeneration, subchondral bone sclerosis, and tibial osteophytes compared with isotype control by day 28. Therapeutic treatment with tanezumab, administered on days 23 and 31 postsurgery, also increased tibial cartilage degeneration by day 37. In contrast, when onset of treatment with tanezumab was delayed to 8 weeks after MMT surgery (given on days 57 and 64), at which time joint damage was more severe and no gait deficiency was noted, there was no increase in cartilage damage by day 71.
One study evaluated the effect of the anti-NGF mAb, muMab 911, in a 28-day rat MIA model. This model is characterized by weight-bearing deficit, mechanical allodynia of the hind paw, cartilage damage, synovitis, and increased numbers of subchondral osteoclasts. Both prophylactic and therapeutic (injections on days 14 and 21) treatment significantly prevented or reversed pain behavior but did not alter cartilage or synovial pathology; isotype control antibody was tested in a separate cohort and behaved similarly to vehicle [26 && ]. However, it can be noted that, as in the meniscal surgery models, that prophylactic treatment resulted in a trend toward an increase in both histological cartilage damage and synovitis scores by day 28, but statistics comparing antibody to vehicle were not presented [26 && ]. Interestingly, both preventive and therapeutic muMab 911 reduced numbers of tartrate resistant acid phosphatase positive osteoclasts in the subchondral bone at the tibial plateau. Similarly, Nwosu et al. [24] tested the effects of the TrkA inhibitor, AR786, in the rat MIA model and found that therapeutic treatment (days 14-21) successfully reversed MIA-induced pain behavior. This was accompanied by a decrease in synovitis score and a trend toward a decrease in macroscopic chondropathy, histologic cartilage degeneration, and histologic calcified cartilage and subchondral bone damage scores by day 21.
Together, these studies support the clinical trial results in that blockade of NGF signaling is effective in treating pain associated with different stages of osteoarthritis, but it may also promote more rapid cartilage degeneration, synovitis, and possibly subchondral bone changes, particularly when treatment starts in the earlier stages of disease. Chondrocytes and synoviocytes are known to express both NGF and TrkA, particularly under pathogenic conditions [5] , but the role of NGF signaling in these tissues has not been fully elucidated, and it is possible that NGF signaling within the joint may also be protective in some way. In addition, anti-NGF treatment in adult rodents has been shown to reduce the function of the sympathetic nervous system [32] [33] [34] [35] . The role of sympathetic nerves in the pathogenesis of osteoarthritis remains unknown, but studies [36, 37] have demonstrated that there are sympathetic nerves associated with neovascularization in the area of the osteochondral junction as well as in osteophytes in osteoarthritis.
Veterinary clinical trials
Both cats and dogs may suffer from degenerative joint disease and associated mobility impairment. As such, there is interest in the veterinary community for novel drugs to treat this condition and as a result of the promising clinical trial data in human osteoarthritis, canine and feline versions of anti-NGF antibodies have been developed. In two recent veterinary clinical pilot studies [27, 28] , a single systemic dose of anti-NGF mAb was able to provide analgesic relief to both dogs and cats with degenerative joint disease. No side-effects were noted, but no assessments of the joint were performed in these studies. Future trials in these communities may represent an opportunity for improving our understanding of the risks/benefits of these drugs by incorporating structural assessments.
CONCLUSION
There is a great deal of enthusiasm regarding the potential of anti-NGF therapy to palliate pain and improve function in patients with severely symptomatic osteoarthritis. Nonetheless, it appears that the benefit carries a risk of exacerbating structural osteoarthritis in several joints. The actual benefits and risks of anti-NGF therapy remain to be fully elucidated; ultimately, however, the proper balance between benefit and risk will be determined by individual patients with their physicians. Preclinical models may be useful for determining which patient populations may be best served as well as how to avoid adverse effects. To date, very few preclinical studies have tested the effects of long-term NGF blockade in experimental osteoarthritis. Nonetheless, it can be anticipated that studies in experimental osteoarthritis will enable researchers to address critical questions that will inform future clinical trials. These include evaluating the effects of intra-articular versus systemic delivery; additional research into the effects of NGF blockade on joint structure, including nonaffected joints; how these effects are dependent on the state of the joint at the start of treatment; and the effect of anti-NGF and NSAID combination treatment. Mechanistic studies are needed for improved targeting of what appears to be a key pathway in osteoarthritis joint pain.
